Company Overview of Miltenyi Biotec Inc.
Miltenyi Biotec Inc. develops, manufactures, and sells products for biomedical research and cellular therapy. It offers its services in the areas of cell biology, immunology, regenerative medicine, and molecular biology. The company was founded in 1989 and is based in Auburn, California. Miltenyi Biotec Inc. operates as a subsidiary of Miltenyi Biotec GmbH.
2303 Lindbergh Street
Auburn, CA 95602
Founded in 1989
Key Executives for Miltenyi Biotec Inc.
Miltenyi Biotec Inc. does not have any Key Executives recorded.
Miltenyi Biotec Inc. Key Developments
GlaxoSmithKline and Miltenyi Biotec Establish Cell, Gene Therapy Collaboration
Mar 16 16
GlaxoSmithKline and Miltenyi Biotec announced a strategic collaboration that will bring together GSK's expertise in developing cell and gene therapy based treatments with Miltenyi Biotec's global leadership in cell processing and related technologies in cell therapy. The collaboration seeks to optimise the manufacture and delivery of these personalised therapies using increased automation and leading edge processing technology. GSK is building a cell and gene therapy R&D platform to underpin development of novel therapies in oncology and rare diseases - two of its core research areas. This reflects the company's belief in cell and gene therapy's potential as an important treatment approach for tackling the underlying cause of serious disease. Through the collaboration, Miltenyi Biotec will engage with GSK to integrate greater automation and high-tech processing technology into GSK's current cell and gene therapy R&D manufacturing capabilities. The goal is to use this increased automation to further industrialise cell and gene therapy, overcoming the manufacturing and scale-up constraints associated with current, more manual cell and gene therapy processes. This could reduce the costs and geographical barriers associated with this treatment approach, speed development of therapies and support their potential beyond rare diseases and limited populations. The collaboration will also bring together the technology and expertise of both companies to advance the discovery of new CAR (chimeric antigen-receptor) T-cell based therapeutics - cells that have been engineered to target and destroy cancer cells by strengthening a patient's natural T-cell response. GSK and Miltenyi Biotec will collaborate on defined CAR-T oncology targets and on the development of advancements in technologies in this space that may be further applied by both companies. This collaboration supplements GSK's existing CAR-T preclinical portfolio.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create
or control the content. For inquiries, please contact Capital IQ directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries